DIG
LCTX icon

Dauntless Investment Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Dauntless Investment Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,614,100
Closed -$2.73M – 79
2025
Q3 		$2.73M Buy
1,614,100
+408,170
+34% +$483K 1.71% 15
2025
Q2 		$731K Buy
+1,205,930
New +$715K 1.27% 13

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dauntless Investment Group's LCTX Position: Q4 2025 in Review

Dauntless Investment Group sold out of Lineage Cell Therapeutics (LCTX) in Q4 2025, closing a stake of 1,614,100 shares — an estimated $2.73M sold.

Dauntless Investment Group first reported a position in LCTX in Q2 2025 and held it in 2 quarters. The position peaked at $2.73M in Q3 2025. 123 funds tracked by Wall St. Rank hold LCTX as of Q4 2025.

  • Dauntless Investment Group reported no remaining Lineage Cell Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Dauntless Investment Group sold 1,614,100 Lineage Cell Therapeutics shares in Q4 2025, an estimated $2.73M.
  • Dauntless Investment Group first reported a position in Lineage Cell Therapeutics in Q2 2025 and held it in 2 quarters.
  • Dauntless Investment Group's Lineage Cell Therapeutics position peaked at $2.73M in Q3 2025.
  • 123 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2025.

Based on Dauntless Investment Group's 13F filing for Q4 2025, filed 17 Feb 2026.